| This week's sponsor is CMIC Group. | |  | |
Today's Rundown Featured Story | | | Tuesday, April 16, 2019 Daphne Koller’s Insitro launched last May with a blog post detailing a broad vision without getting too deep into the weeds. Now, Insitro is ready to share a little more—starting with a Gilead partnership worth $15 million upfront, but that could total more than $1 billion. |
|
|
Top Stories Tuesday, April 16, 2019 Ophthotech is changing its name to Iveric bio as part of its transition into a gene therapy biotech. The rebranding follows a period in which Ophthotech responded to a phase 3 setback by striking deals for retinal disease gene therapies. Tuesday, April 16, 2019 Paul-Peter Tak, previously chief immunology officer at GlaxoSmithKline, has signed on to lead Kintai Therapeutics as it steers a pipeline of “precision enteric medicines” toward the clinic, with the first programs slated to enter phase 1 as early as next year. Monday, April 15, 2019 Mitotech – a biotech specializing in targeting mitochondria – is moving into late stage of clinical development in Dry Eye Disease. Tuesday, April 16, 2019 Achaogen is looking to sell its assets and close out its affairs through the bankruptcy process. News of the Chapter 11 filing comes 10 months after Achaogen won FDA approval for its antibiotic Zemdri. Tuesday, April 16, 2019 As CRISPRomics biotech KSQ Therapeutics gears up for its first clinical trial next year, it’s hired biopharma veteran Beni Wolf, M.D., Ph.D., as its chief medical officer. Tuesday, April 16, 2019 Roland Bürli, Ph.D., who headed up neuroscience medicinal chemistry at AstraZeneca, joins Cerevance as the CNS-focused biotech looks to advance a suite of treatments for Parkinson’s and Alzheimer’s disease. Monday, April 15, 2019 Researchers in Israel have printed a three-dimensional human heart using bioinks developed from a patient’s own cells, which they say makes it completely biocompatible with the donor. Tuesday, April 16, 2019 Look out, Roche and Regeneron—Novartis eye candidate brolucizumab is on its way. Monday, the FDA said it had granted the wet age-related macular degeneration prospect a quick review, putting it on track to launch in six months. | This week's sponsor is Sensors Expo. | |  | |
Resources Presented by: Total Brain Total Brain Announces Personalized Test for Treatment Prediction in Depression with 80% Accuracy. Sponsored by: Veradigm Prescription price transparency technology is here – but is it making a difference? Find out HERE. Sponsored by: Strativity Every life sciences firm talks about patient-centricity, but are you doing what it takes to deliver? Sponsored by: USDM Life Sciences The year’s biggest compliance and technology trends in life sciences. Learn about the latest trends impacting the biotech, medical device and pharmaceutical industries. Sponsored by: Eurofins Discovery Learn how to utilize allosteric modulation to maximize its full potential in drug discovery programs. Download this white paper to learn more. Sponsored by: BioAnalytix, Inc. Discussion of the potential for improving biologic drug development success through earlier, strategic application of advanced mass spectrometry, because currently, with most biologic drugs, including gene therapies, failures are realized in late-stage development, after substantial investment has been made in a candidate. Sponsored by: PointCross Life Sciences Clinical trials and biomarker data from patients when unified, harmonized, and made searchable; is a rich, reliable and controlled resource for research. This paper sets out the requirements for a Translational and Biomarker Research Workbench for scientists using the experiences from use of Xbiom™ at BioPharma. Sponsored by: Unchained Labs Download this whitepaper to learn more! Sponsored by: Patheon, part of Thermo Fisher Scientific Is Flow Chemistry right for your API Development? Sponsored by: Veradigm Real-World case study by Veradigm suggests that new medications specifically approved for the treatment of systolic heart failure may be underutilized despite being important advances in patient care. Sponsored by: Outer Edge Technology Software end of life puts you at risk for data breaches, business disruption and liability. Support for Microsoft SQL Server 2008/2008 R2 and Windows Server 2008/2008 R2 ends on July 9, 2019 and January 14, 2020, respectively. Learn how you can turn these risks into a strategic business advantage. Sponsored by: AlphaSense From new regulations to drug pricing and the latest M&A deals, learn how AI is making it easier for competitive intelligence to uncover the insights they need to stay ahead of the curve. Sponsored by: InterSystems Whitepaper on leveraging normalized real-world patient data to streamline clinical trials, reduce delays and lower costs. Sponsored by: InterSystems Analytics using patients’ real-time longitudinal laboratory results, and claims data, yielded higher value information and new revenue streams for TriCore reference laboratories. Sponsored by: Biotech Primer The Biopharma industry is moving at lightning speed and it can be a challenge to keep pace. Here at Biotech Primer we spend hours each week researching, writing, and editing original content for the Biotech Primer WEEKLY with one goal in mind: to help everyone better understand the latest science and technology driving today’s healthcare industry. | 
